246 related articles for article (PubMed ID: 33890819)
1. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
Wu CS; Shang CY; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
[No Abstract] [Full Text] [Related]
2. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
[TBL] [Abstract][Full Text] [Related]
5. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
[TBL] [Abstract][Full Text] [Related]
7. Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial.
Taş Torun Y; Işik Taner Y; Güney E; İseri E
Appl Neuropsychol Child; 2022; 11(4):567-578. PubMed ID: 32757634
[TBL] [Abstract][Full Text] [Related]
8. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
9. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
[TBL] [Abstract][Full Text] [Related]
11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
Shih HH; Shang CY; Gau SS
J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):9-19. PubMed ID: 30457349
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
17. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
18. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
[TBL] [Abstract][Full Text] [Related]
19. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
Gau SS; Shang CY
Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
[TBL] [Abstract][Full Text] [Related]
20. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
Hammerness P; Georgiopoulos A; Doyle RL; Utzinger L; Schillinger M; Martelon M; Brodziak K; Biederman J; Wilens TE
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):493-9. PubMed ID: 19877973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]